

Avra Laboratories Product List



Active Pharma Ingredients

Product	Therapeutic Category	Present Status	Plant Validation	Filing	CAS No.
Exatecan Mesylate Di-hydrate	Oncology	Under Development	Q3FY24		197720-53-9
Irinotecan Hydrochloride	Oncology	Commercial	Completed	CEP under filing	136572-09-3
Lenalidomide (Form-I, Form-B, Form-A*)	Oncology	Commercial			847871-99-2 (Form B)
Topotecan Hydrochloride	Oncology	Under Development			119413-54-6
Methotrexate	Oncology	Under Development	Q4FY24		59-05-2

*Form-A process available, can be validated as per requirement

Avra Laboratories Product List



ADC Payloads Under Development

Product	Therapeutic Category	Use	Present Status	Sample Availability	CAS No.
MMAE (Auristatin)	Oncology	ADC payloads	Under Development	Q3FY24	474645-27-7
MMAF (Auristatin)	Oncology	ADC payloads	Under Development	Q3FY24	745017-94-1
DM1 (Maytansinoid)	Oncology	ADC payloads	Under Development	Q4FY24	1018448-65-1
DM4 (Maytansinoid)	Oncology	ADC payloads	Under Development	Q4FY24	1453084-37-1
SN-22	Oncology	ADC payloads	Technology Available. Can be taken-up on request		17403-07-5
Silatecan	Oncology	ADC payloads			220913-32-6
Rubitecan	Oncology	ADC payloads			91421-42-0
Belotecan	Oncology	ADC payloads			213819-48-8

Avra Laboratories Product List



Pharmaceutical Intermediates

Product	Therapeutic Category	Use	Present Status	Plant Validation	CAS No.
7-Ethyl-10-hydroxycamptothecin (SN-38)	Oncology	Irinotecan intermediate	Commercial	Validated	86639-52-3
(S)-8-Ethyl-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-aza-cyclopenta [b]naphthalene-1,4,7-trione (S-trione)	Oncology	Oncology intermediate	Commercial	Validated	110351-94-5
3 -Amino-Piperidine-2,6-Dione HCl	Oncology	Lenalidomide intermediate	Commercial		24666-56-6
3-Nitro-2- Bromomethyl Methyl Benzoate	Oncology	Lenalidomide intermediate	Commercial	Validated	98475-07-1
N-(4-(methylamino)benzoyl)-l-glutamic acid diethyl ester	Oncology	Methotrexate intermediate	Commercial		2378-95-2
2'-Amino-5'-hydroxypropiophenone (AHP)	Oncology	Irinotecan intermediate	Commercial		35364-15-9